Evaluation of Dalfampridine Extended Release 5 and 10 mg in Multiple Sclerosis: A Randomized Controlled Trial

Background: Dalfampridine extended-release (ER) tablets, 10 mg twice daily, have been shown to improve walking in people with multiple sclerosis. We evaluated the safety and efficacy of dalfampridine-ER 5 mg compared with 10 mg. Methods: Patients were randomized to double-blind treatment with twice-...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Int J MS Care
Autori principali: Yapundich, Robert, Applebee, Angela, Bethoux, Francois, Goldman, Myla D., Hutton, George J., Mass, Michele, Pardo, Gabriel, Klingler, Michael, Henney, Herbert R., Blight, Andrew R., Carrazana, Enrique J.
Natura: Artigo
Lingua:Inglês
Pubblicazione: The Consortium of Multiple Sclerosis Centers 2015
Soggetti:
Articles
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4455866/
https://ncbi.nlm.nih.gov/pubmed/26052259
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7224/1537-2073.2014-040
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi